SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-233986
Filing Date
2021-08-03
Accepted
2021-08-03 07:01:02
Documents
14
Period of Report
2021-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d183419d8k.htm   iXBRL 8-K 25875
2 EX-99.1 d183419dex991.htm EX-99.1 92073
6 GRAPHIC g183419dsp1.jpg GRAPHIC 2609
  Complete submission text file 0001193125-21-233986.txt   257386

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20210803.xsd EX-101.SCH 2884
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20210803_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20210803_pre.xml EX-101.PRE 10947
7 EXTRACTED XBRL INSTANCE DOCUMENT d183419d8k_htm.xml XML 3297
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 211137930
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences